Mechanistic Approach into 1,2,3-triazoles-based IIIM(S)-RS98 Mediated Apoptosis in Lung Cancer Cells

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Lung cancer is a leading cause of cancer-related deaths globally.
• There is a critical need for novel therapeutic agents to combat lung cancer.
• 1,2,3 triazole derivatives show promise as anti-cancer drugs.

Purpose of the Study:

• To evaluate the anti-lung cancer efficacy of a novel 1,2,3 triazole compound, IIIM(S)-RS98.
• To investigate the cytotoxic potential and mechanism of action of IIIM(S)-RS98 against various cancer cell lines.

Main Methods:

• In vitro cytotoxicity assays on multiple cancer cell lines and normal cells.
• Flow cytometry to assess apoptosis, mitochondrial membrane potential, ROS, nitric oxide, and cell cycle.
• Western blotting to analyze key proteins in apoptotic and signaling pathways.
• Molecular docking to predict interactions with target proteins.

Main Results:

• IIIM(S)-RS98 exhibited potent cytotoxicity against A549 lung cancer cells with a selectivity index of 8.16.
• The compound induced apoptosis, G1 cell cycle arrest, and inhibited cell migration and clonogenic potential.
• IIIM(S)-RS98 modulated the PI3K/Akt pathway, leading to apoptosis via caspase activation and altered Bcl-2/Bax expression.

Conclusions:

• IIIM(S)-RS98 demonstrates significant anti-lung cancer activity through multiple mechanisms, including apoptosis induction.
• The compound's ability to target key cancer pathways suggests its potential as a novel therapeutic agent for lung cancer.
• Further investigation into IIIM(S)-RS98 is warranted for its development as a lung cancer treatment.